Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

SHE:300497 Revenue

Jiangxi Fushine Pharmaceutical had revenue of 530.49M CNY in the quarter ending June 30, 2026, with 88.80% growth. This brings the company's total for the last twelve months to 1.56B, up 54.30% year-over-year. In the year 2025, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B with 0.61% growth. That makes Jiangxi Fushine Pharmaceutical the 16,327th largest company in the world by revenue and 2,934th in China.

• Revenue (ttm): 1.56B
• Revenue Growth: +54.30%
• P/S Ratio: 4.82
• Revenue / Employee: n/a
• Employees: 1,663
• Market Cap: 7.80B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Manufacturing 814.22M 68.7%
• Lithium Battery Electrolyte Additive 368.77M 31.1%
• CDMO 1.99M 0.2%

By Geography

Chart

• China 943.44M 79.6%
• Foreign 241.54M 20.4%

Fiscal year ended Dec 31, 2025 See the full SHE:300497 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.18B	7.14M	0.61%
Dec 31, 2024	1.18B	-431.82M	-26.83%
Dec 31, 2023	1.61B	-37.59M	-2.28%
Jan 1, 2023	1.65B	217.72M	15.23%
Jan 1, 2022	1.43B	-63.41M	-4.25%

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error